Drug Profile
Imetelstat - Geron Corporation
Alternative Names: GRN 140719; GRN 163; GRN 163-L; GRN 719; GRN163L peptide; Imetelstat sodium; JNJ-63935937Latest Information Update: 24 Apr 2024
Price :
$50
*
At a glance
- Originator GCP-Service International; Geron Corporation
- Developer GCP-Service International; Geron Corporation; Janssen Biotech
- Class Antifibrotics; Antineoplastics; Lipids; Oligonucleotides
- Mechanism of Action Telomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Myelodysplastic syndromes
- Phase III Myelofibrosis
- Phase II Acute myeloid leukaemia
- Suspended Multiple myeloma
- No development reported Chronic myeloid leukaemia
- Discontinued Breast cancer; Essential thrombocythaemia; Lymphoproliferative disorders; Non-small cell lung cancer; Polycythaemia vera; Solid tumours